← Back

$ Value

$0

Shares

478,800

Price

$0

Filed

Aug 29

Insider

Name

Zindrick Thomas

Title

President and CEO

CIK

0001937573

Roles

Officer

Transaction Details

Transaction Date

2025-08-27

Code

A

Table

Derivative

Ownership

Direct

Equity Swap

No

Shares After

478,800

Footnotes

Represents restricted stock units ("RSUs") granted pursuant to the Issuer's 2022 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of common stock upon vesting. The RSUs will vest 25% on the first anniversary of the date of grant, and the remaining shares shall vest in 12 equal quarterly (every 3 months) installments thereafter. | Includes 1514 shares of common stock acquired under the Issuer's Employee Stock Purchase Plan. | The shares subject to the option will vest 25% on the first anniversary of the date of grant, and the remaining shares shall vest in 36 equal monthly installments thereafter.

Filing Info

Accession No.

0001641172-25-026002

Form Type

4

Issuer CIK

0001231457

Zindrick Thomas's History

Date Ticker Type Value
2026-03-24 GNLX $9K
2025-11-17 GNLX $24K
2025-09-01 GNLX D
2025-09-01 GNLX A
2025-09-01 GNLX D
2025-09-01 GNLX A
2025-09-01 GNLX D
2025-09-01 GNLX A
2025-09-01 GNLX D
2025-09-01 GNLX A

Other Insiders at GNLX (90d)

Insider Bought Sold Last
Yu Yong / Cappello Joseph
SVP, Clinical Development
$2K 2026-03-24
Zindrick Thomas
President and CEO
$9K 2026-03-24
Thomas John $29K 2026-03-02
Smalling Ralph
Head of Regulatory
$1K 2026-03-25